Join Growin Stock Community!

Delcath systems, inc.DCTH.US Overview

US StockHealthcare
(No presentation for DCTH)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

DCTH AI Insights

DCTH Overall Performance

DCTH AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

DCTH Recent Performance

1.35%

Delcath systems, inc.

0.05%

Avg of Sector

-0.31%

S&P500

DCTH PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

DCTH Key Information

DCTH Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

DCTH Profile

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.

Price of DCTH

DCTH FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

DCTH Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
0.03
PE Ratio (TTM)
296.67
Forward PE
14.67
PS Ratio (TTM)
3.69
PB Ratio
2.73
Price-to-FCF
26.00
METRIC
VALUE
vs. INDUSTRY
Gross Margin
86.29%
Net Margin
1.50%
Revenue Growth (YoY)
251.54%
Profit Growth (YoY)
273.09%
3-Year Revenue Growth
183.13%
3-Year Profit Growth
199.01%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
0.03
PE Ratio (TTM)
296.67
Forward PE
14.67
PS Ratio (TTM)
3.69
PB Ratio
2.73
Price-to-FCF
26.00
Gross Margin
86.29%
Net Margin
1.50%
Revenue Growth (YoY)
251.54%
Profit Growth (YoY)
273.09%
3-Year Revenue Growth
183.13%
3-Year Profit Growth
199.01%
  • When is DCTH's latest earnings report released?

    The most recent financial report for Delcath systems, inc. (DCTH) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating DCTH's short-term business performance and financial health. For the latest updates on DCTH's earnings releases, visit this page regularly.

  • Where does DCTH fall in the P/E River chart?

    According to historical valuation range analysis, Delcath systems, inc. (DCTH)'s current price-to-earnings (P/E) ratio is 267.65, placing it in the Watch zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning optimistic. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.

  • What is the operating profit of DCTH?

    According to the latest financial report, Delcath systems, inc. (DCTH) reported an Operating Profit of -388K with an Operating Margin of -1.89% this period, representing a growth of 69.18% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is DCTH's revenue growth?

    In the latest financial report, Delcath systems, inc. (DCTH) announced revenue of 20.56M, with a Year-Over-Year growth rate of 83.6%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much debt does DCTH have?

    As of the end of the reporting period, Delcath systems, inc. (DCTH) had total debt of 965K, with a debt ratio of 0.01. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does DCTH have?

    At the end of the period, Delcath systems, inc. (DCTH) held Total Cash and Cash Equivalents of 41.81M, accounting for 0.34 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does DCTH go with three margins increasing?

    In the latest report, Delcath systems, inc. (DCTH) did not achieve the “three margins increasing” benchmark, with a gross margin of 87.2%%, operating margin of -1.89%%, and net margin of 4%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess DCTH's profit trajectory and future growth potential.

  • Is DCTH's EPS continuing to grow?

    According to the past four quarterly reports, Delcath systems, inc. (DCTH)'s earnings per share (EPS) shows a declining trend, with the latest EPS at 0.02. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of DCTH?

    Delcath systems, inc. (DCTH)'s Free Cash Flow (FCF) for the period is 4.31M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 211.85% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.